United States ex rel. Polansky v. Pfizer, Inc.

762 F.3d 160, 2014 WL 3844149
CourtCourt of Appeals for the Second Circuit
DecidedAugust 6, 2014
DocketDocket No. 12-5008-cv
StatusPublished
Cited by15 cases

This text of 762 F.3d 160 (United States ex rel. Polansky v. Pfizer, Inc.) is published on Counsel Stack Legal Research, covering Court of Appeals for the Second Circuit primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
United States ex rel. Polansky v. Pfizer, Inc., 762 F.3d 160, 2014 WL 3844149 (2d Cir. 2014).

Opinion

GERARD E. LYNCH, Circuit Judge:

Plaintiff-appellant Jesse Polansky appeals a dismissal of his claims against defendant-appellee Pfizer, Inc. for alleged violations of the False Claims Act and state law equivalents. From 2001 to 2003, Po-lansky, a medical doctor, worked at Pfizer, and during his tenure he came to believe that Pfizer had violated various laws. He complained internally about the alleged violations and those complaints allegedly gave rise to escalating conflicts with his supervisors and to his eventual dismissal. Polansky filed this action shortly thereafter charging the company with two sets of related violations. The district court (Brian M. Cogan, Judge) entered judgment dismissing some or all of Polansky’s claims. The question for us is whether we lack jurisdiction over Polansky’s appeal from that judgment because we cannot discern how much of the complaint the district court intended to dismiss. We hold that we do and dismiss Polansky’s appeal.

BACKGROUND

Polansky served as Pfizer’s Director of Outcomes Management Strategies, and, in that capacity, he served on a committee that reviewed marketing strategies for certain drugs. One of those drugs was Lipitor — a statin that lowers cholesterol levels by blocking enzymes that drive cholesterol production. Polansky believed that Pfizer’s marketing misled doctors into over-prescribing Lipitor for off-label uses, and that those prescriptions, written based on allegedly false assumptions, caused federal and state health programs to reimburse patients for the cost of drugs they did not need. He repeatedly voiced these fears, as well as concerns regarding sexual harassment in his department, to supervisors. According to Polansky, his supervisors demanded that he remain silent. He refused. Tensions mounted. He was fired.

Polansky then filed suit, accusing Pfizer of violating the law in two different ways. The bulk of his complaint charged Pfizer with defrauding the federal and state governments; his final amended complaint spent 114 pages detailing the Medicare and Medicaid reimbursement system, the regulatory structure governing Lipitor’s use, and Pfizer’s aggressive marketing of Lipitor to patients for whom lifestyle changes would have been sufficient to lower their cholesterol. Toward the end of his complaint, however, Polansky also claimed that Pfizer fired him for reporting these violations to management and supervisors; in fourteen pages, he described the alleged timing and frequency of his internal protests regarding Lipitor’s marketing, his effort to report sexual harassment problems in his department, and the company’s decision to fire him. In all, Polan-sky charged Pfizer with eighteen counts of fraud and five counts of illegal retaliation.1 Given that imbalance, it is not surprising [162]*162that the parties and the district court spent more time unraveling the complicated and substantial fraud claims than on evaluating Pfizer’s choice to fire Polansky.

Pfizer twice moved to dismiss the action. Its first motion attacked Polansky’s Fourth Amended Complaint as failing to state a claim pursuant to the False Claims Act and insufficiently pleading fraud under Rule 9(b). The motion also argued that Polansky’s internal complaints were not protected activity under the federal False Claims Act or New York State’s whistle-blower-protection statute because he asked Pfizer only to alter its marketing strategy, and never requested that the company return profits obtained after patients submitted “false claims” to government insurance programs. In a lengthy order, the district court (per Judge Edward R. Korman, to whom the case was then assigned) granted Pfizer’s motion in part, dismissing Polan-sky’s false claims counts on grounds of failure to plead fraud with sufficient particularity, but granted him leave to replead. United States ex rel. Polansky v. Pfizer, Inc., 04-CV-0704 (ERK), 2009 WL 1456582, at *11 (E.D.N.Y. May 22, 2009) (“Polansky I”). In a separate two-page order, the district court declined to dismiss the two challenged retaliation claims, which related only to the allegation that Polansky was fired for reporting fraud. Polansky had also alleged that his employers fired him for bringing to light sexual harassment in his department, and the district court reasoned that no efficiency would be gained by dismissing the challenged claims because the facts surrounding Polansky’s firing would have to be adjudicated regardless of the court’s decision. District Court Docket # 61. The court, however, noted that its decision was bounded by its view of the case “at this stage of the litigation,” implying that it might revisit the motion in the future. Id.

After Polansky filed an amended complaint, Pfizer again moved to dismiss, challenging only the revamped fraud claims. Some time thereafter, the case was transferred to Judge Cogan, who may or may not have reviewed the prior decision regarding the retaliation claims. In any event, the district court granted Pfizer’s motion. In an opinion that exclusively addressed the merits of Polansky’s allegations of marketing misrepresentations, the court concluded, as a matter of law, that Pfizer “ha[d] not engaged in off-label marketing of Lipitor according to plaintiffs allegations.” United States ex rel. Polansky v. Pfizer, Inc., 914 F.Supp.2d 259, 266 (E.D.N.Y.2012) (“Polansky II”). But the court made no mention of Polansky’s outstanding retaliation claims, and it remained unclear whether it intended to dismiss those counts, whether it overlooked those claims, or whether it intended to only dismiss the fraud claims. The court’s concluding language deepened that ambiguity. In one sentence, it “granted” Pfizer’s “motion to dismiss,” which had not sought dismissal of the retaliation claims; in the following sentence, however, it directed “[t]he Clerk ... to enter judgment in favor of defendant, dismissing the complaint,” presumably in its entirety. .Id.

DISCUSSION

Our jurisdiction over this appeal is bounded by 28 U.S.C. § 1291, which empowers us to hear only “appeals from [163]*163... final decisions” of the federal district courts. “[T]he statute ... disallow[s] appeal from any decision which is tentative, informal or incomplete[, because an] [alp-peal gives the upper court a power of review, not one of intervention.” Cohen v. Beneficial Indus. Loan Corp., 337 U.S. 541, 546, 69 S.Ct. 1221, 93 L.Ed. 1528 (1949). To test for finality, reviewing courts employ a “practical rather than a technical” analysis. Id. Such a “pragmatic approach to the question of finality [is] ... essential to the achievement of the just, speedy, and inexpensive determination of every action.” Brown Shoe Co. v. United States, 370 U.S. 294, 306, 82 S.Ct. 1502, 8 L.Ed.2d 510 (1962) (quotation marks omitted). Thus, if a “matter remains open, unfinished or inconclusive, there may be no intrusion by appeal.” Cohen, 337 U.S. at 546, 69 S.Ct. 1221. In contrast, if the district court only overlooked a “ministerial dut[y],” any omission “is not fatal to finality and consequent appealability.” Taylor v. Bd. of Educ., 288 F.2d 600, 602 (2d Cir.1961).

Free access — add to your briefcase to read the full text and ask questions with AI

Related

Bradley v. Charles
Second Circuit, 2025
Leon v. Cleansource Inc.
S.D. New York, 2024
Fisher v. SD Protection Inc.
948 F.3d 593 (Second Circuit, 2020)
United States ex rel. Polansky v. Pfizer, Inc.
822 F.3d 613 (Second Circuit, 2016)
Prince Services International Inc. v. Ethiopian Airlines
646 F. App'x 45 (Second Circuit, 2016)
Lauro v. Commissioner of Social Security
644 F. App'x 88 (Second Circuit, 2016)
Cox v. United States
783 F.3d 145 (Second Circuit, 2015)
Conte v. County of Nassau
596 F. App'x 1 (Second Circuit, 2014)
Encarnacion v. Goord
580 F. App'x 19 (Second Circuit, 2014)

Cite This Page — Counsel Stack

Bluebook (online)
762 F.3d 160, 2014 WL 3844149, Counsel Stack Legal Research, https://law.counselstack.com/opinion/united-states-ex-rel-polansky-v-pfizer-inc-ca2-2014.